Health systems are utilizing insulin dosing algorithms (IDA) within the EMR to adjust IV insulin (IVI). EndoTool IV (ETIV) is IDA software for blood glucose (BG) management which evaluates BG values to recommend IV insulin/dextrose doses to adjust the BG level within a target range. ETIV was integrated with our EMR as part of a quality project to reduce hypoglycemia in IVI patients. The tool was started in two of our ICUs that treat our DKA admissions. Dashboards capture BG values defined as hypoglycemia BG less than 70 mg/dL, severe hypoglycemia BG less than 40 mg/dL, and length of hospital stay for diabetic ketoacidosis (DKA LOS). Dosing modalities were available for hyperglycemia, HHS or DKA; 90% of ordering providers selected the hyperglycemia mode. We report results on the first 437 patient runs. The population was 60 % type 2 DM, 16 % type 1 and the remainder unknown. Average BG at IVI start was 221.5 mg/dL with an average time to goal of 4.7 hours. This translated to an average time on IVI of 15.5 hours for the group studied. Adoption of ETIV was associated with an approximate 5-fold reduction in hypoglycemic BG values, elimination of observed severe hypoglycemic BG values and a reduction in length of stay for DKA LOS. We conclude that ETIV is effective in reducing hypoglycemic events in persons treated with IVI and may reduce DKA LOS. Hospital systems considering a quality improvement project to reduce inpatient hypoglycemia for IVI should consider adopting an IDA. Disclosure J.Aloi: Research Support; Abbott Diabetes, Medtronic. C.E.Price: None. C.O.Usoh: None. K.Dunn: None.

Introduction: Hospital readmissions are more common in persons admitted with diabetes as a primary diagnosis, accounting for approximately 20% of unplanned readmissions.1 Poor clinical outcomes and higher costs result.2 Helping people remain out of the hospital with improved diabetes self-management is both patient-centered and cost effective.1 Remote patient care improves access to care, removes transportation as a barrier and lessens the time required versus in person diabetes visits.3 Methods: The glucose management team (GMT) at Atrium Health Wake Forest Baptist Medical Center, comprised of advanced practice providers and an endocrinologist, offered post-discharge telehealth visits within 7 days to patients with insulin treated complex diabetes from 1/1 - 3/24/21. Patients’ diabetes regimens and glucose readings were reviewed and recommendations for treatment changes were offered. Results: A total of 88 patients were scheduled for post-discharge visits, and 55.7% (n=49) participated in a scheduled telehealth visit, while 36.4% did not (n=32) . Of patients who no-showed, there were zero 30 day readmissions and fourteen 90 day readmissions (43.8%) . Of patients who had a telehealth visit, there were two 30 day readmissions (4%) and eleven 90 day readmissions (22.4%) . Odds ratio for 90 day readmission was 2.69 (p=0.042) in those who did not attend a post-discharge telehealth visit. Conclusion: While 30-day readmissions were higher in the group that had a telehealth visit, this may be due to global struggles with nonadherence in the no-show group. An odds ratio of over 2.5 for 90 day readmission compared to patients who completed a post-discharge telehealth visit supports this view. Post-discharge telehealth visits decreased unplanned readmissions at 90 days by providing access to expert clinicians for support, instruction on self-directed glucose management and treatment regimen recommendations. Disclosure A.Johns: None. C.E.Price: None. J.A.Aloi: Research Support; Abbott Diabetes, Medtronic. C.Burns: None.